11:26 , Sep 28, 2018 |  BC Extra  |  Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
18:53 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

NovaBiotics Ltd. (Aberdeen, U.K.) said oral Lynovex cysteamine (formerly NM001) as an adjunct to standard of care (SOC) significantly improved health-related questionnaire scores and reduced respiratory symptom severity compared with SOC alone in the Phase...
00:55 , Feb 14, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Aneurysm Mouse studies suggest the CysLT1 inhibitor Singulair montelukast could help treat abdominal aortic aneurysm (AAA). In a mouse model of calcium chloride-induced AAA, Singulair decreased aortic dilation compared with no treatment. In a...
02:53 , Dec 8, 2017 |  BC Week In Review  |  Company News

Mero licenses AAT deficiency candidate from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an exclusive license and option to acquire AZD9668, an oral inhibitor of neutrophil elastase (ELANE; NE; HLE) which is in development to treat alpha-1 antitrypsin...
00:28 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Antabio raises EUR7.3M series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) on Oct. 16 in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors...
22:13 , Oct 16, 2017 |  BC Extra  |  Financial News

Antabio raises €7.3M in series A

Antabio S.A.S. (Labege, France) said it raised €7.3 million ($8.6 million) in a series A round from iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion, and private individuals. Antabio is developing inhibitors of bacterial metalloenzymes...
21:16 , May 17, 2017 |  BC Week In Review  |  Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

Proteon Therapeutics Inc. (NASDAQ:PRTO) said FDA granted breakthrough therapy designation to vonapanitase to increase arteriovenous fistula (AVF) secondary patency in patients on or expected to start hemodialysis. The recombinant human elastase is in the Phase III...
20:36 , May 12, 2017 |  BC Week In Review  |  Clinical News

Proteon ups Phase III PATENCY-2 enrollment

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical...
16:25 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph III PATENCY-2 amended

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to increase enrollment to 500 patients from 300 and to establish secondary patency and fistula use for...